EXO Biologics
Hugues Wallemacq is a seasoned professional with extensive experience in the life sciences and biopharmaceutical sectors. Currently serving as Chief Executive Officer and Chief Operations Officer at EXO Biologics since June 2021, Hugues also holds the position of Investment Manager at Noshaq since January 2020. Previous roles include Board Member and Head of Business Development at Unisensor, and Director of Clinical Immuno-Chemistry Assays at GSK. Hugues possesses a PhD in Immunology from the Université de Liège, where research was conducted under the guidance of Pr Fabrice Bureau, as well as an Executive MBA from Maastricht University School of Business and Economics. Starting a career as a Veterinarian in French veterinary clinics, Hugues holds a Doctor of Veterinary Medicine degree from the University of Liège.
This person is not in any teams
EXO Biologics
EXO Biologics is a Belgian clinical-stage biotechnology company focusing on researching and developing novel sub-cellular therapeutic candidates based on exosomes. Exo Biologics mission is to provide affordable and accessible exosomes therapies to patients with unmet medical needs. Exo Biologics has strong partnerships and influential networks for collaborating and researching new medical treatments, including research centers, public universities, and private partners.